Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Primary Myelofibrosis 3Polycythemia Vera 2Myelodysplastic Syndromes 2Lymphoma, T-Cell 2Leukemia 2Graft vs Host Disease 2Thrombocythemia, Essential 1Thalassemia 1Preleukemia 1Precancerous Conditions 1Neoplasms by Histologic Type 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Hematologic Diseases 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Bone Marrow Diseases 1

Interventions

durvalumab 2ruxolitinib 1repotrectinib 1cemiplimab 1atezolizumab 1Pemetrexed 1Nivolumab 1Immunotherapy 1Docetaxel 1Cisplatin 1CPI-0610 1Biopsy 1Bevacizumab 1ALT-803 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × ruxolitinib × 30 days × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡